Day 1 :
Ovarian Cancer Institute, USA
Keynote: Modern management of ovarian cancer
Time : 09:15-10:00
Benedict B Benigno is a world-renowned Gynecologic Surgeon and Oncologist who has spent his career treating women with ovarian cancer. In 1999, he founded the Ovarian Cancer Institute and serves as its CEO. He received his MD degree from the Georgetown University School of Medicine, and completed his residency in Obstetrics and Gynecology at St. Vincent’s Hospital and Medical Center in New York City. He completed two fellowships in Gynecologic Oncology, one at the Emory University School of Medicine in Atlanta and the other at the M D Anderson Hospital and Tumor Institute in Houston. He is the Founder and President of University Gynecologic Oncology and the Director of Gynecologic Oncology at Northside Hospital in Atlanta, Georgia. He is a member of many societies including the Society of Gynecologic Oncologists, the Felix Rutledge Society, and the American Society of Clinical Oncologists. He is a Clinical Professor in the Department of Obstetrics and Gynecology at the Emory University School of Medicine, the Morehouse School of Medicine, and Mercer University. He serves on the board of the Parker H Petit Institute of Bioengineering and Bioscience at the Georgia Institute of Technology. He has published numerous articles and textbook chapters, and travels the world speaking on various aspects of gynecologic cancer. He is the author of the book, “The Ultimate Guide to Ovarian Cancer: Everything You Need to Know about Diagnosis, Treatment, and Research”. He was honored in 2002 with the Hero of Medicine Award for the Most Innovative Cancer Research in the State of Georgia. In 2014, he was appointed to the ovarian cancer steering committee based in the National Institute of Health.
Ovarian cancer is treated with a combination of surgery and chemotherapy. Both forms of therapy are important as one without the other is virtually synonymous with a recurrence. The history of the disease along with its presentation and current management will be reviewed as a prelude to the discussion of advanced forms of therapy, including HIPEC, targeted treatment, and immunotherapy. Most patients present in advanced stages and so the recurrence rate remains at an unacceptable 80%. The CA-125 blood test has been around for almost 40 years and is absolutely useless as a diagnostic test. An exciting new test for ovarian cancer, which appears to be 100% sensitive AND specific, will be described in detail. The interesting 15 year journey to its discovery will be discussed along with its possible use as a mass-screening tool along with the annual pap smear for cervical cancer
Ukrainian Anti-Cancer Institute, Austria
Keynote: Anti-cancer preparation Nsc 631570 and its efficacy in the treatment of children with various cancer diseases
Time : 10:00-10:40
Wassil Nowicky obtained Diploma and is the Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. He is the inventor of the anti-cancer preparation on basis of celandine alkaloids “NSC-631570”.
In accordance with the results of the latest scientific studies cancer cells have a more negative charge than normal cells. Thus many scientists and doctors try to use this factor in the treatment of cancer patients, creating the positive charged ions in tumors. NSC 631570 consists of positive charged ions of greater celandine alkaloids. After administration they accumulate in tumors very fast that can be seen under the UV-light thanks to the autofluorescence ability of the preparation. NSC 631570 is the first and only cancer preparation with a selective effect that has been confirmed by 120 universities and research centers in the world. The next indications were provided by clinical use, where NSC631570 caused no noteworthy side-effects. It improves patients’ general condition as well as regenerates their immune system which is important especially in cases of patients whose immune system has been impaired by chemotherapy and radiotherapy significantly. It is well-known that the immune system of children can be regenerated faster and better than the immunse system of adults. The studies conducted with the NSC 631570 in cases of treatment of 203 cancer patients with various cancer diseases, among which there were 16 children, have shown the results as follows: among adults there was a complete remission in 16.58% of cases, it was possible to achieve a partial remission in 62.57% of cases and for 20.86% of patients there was no influence. At the same time the results with children were as follows: complete remission 62.5%, partial remission 31.25% and no influence 6.25%. During the treatment of children with cancer it has also been proven that using the NSC 631570 brought a significant success in cases of treatment of children with such diagnoses as Xeroderma Pigmentosum and Ewing’s Sarcoma. The aim of the presentation is to pay attention of the scientific world on the treatment of children with various cancer diseases with help of the anticancer preparation NSC 631570.